Edition:
India

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

4.60USD
23 Apr 2018
Change (% chg)

$-0.03 (-0.65%)
Prev Close
$4.63
Open
$4.61
Day's High
$4.64
Day's Low
$4.48
Volume
3,180
Avg. Vol
17,340
52-wk High
$6.34
52-wk Low
$2.65

Select another date:

Tue, Apr 10 2018

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan

* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

* CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA

BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

* CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION Source text: (http://bit.ly/2ER7sY9) Further company coverage:

BRIEF-Caladrius Biosciences reports 2017 third quarter results

* Q3 loss per share $0.38 from continuing operations Source text for Eikon: Further company coverage:

Select another date: